Back
IMCAK
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Immuron Limited - Option Expiring 27-Jun-2019 Deferred
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in IMCAK
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in IMCAK
N/A
IMCAK investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in IMCAK also invest in...
Want more shares? Try these...
Immuron Ltd. engages in the research and development of oral immunotherapy, which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The company is headquartered in Melbourne, Victoria and currently employs 5 full-time employees. The firm operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. Its flagship products include Travelan and Protectyn. Travelan is a licensed natural health product and is indicated to reduce the risk of Travellers’ Diarrhea. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn product helps to promote digestion and healthy gastrointestinal system health; support and maintain healthy liver function, and enhance immune defenses.
📊 Share price